Alpha Tau Completes Enrollment in Pivotal U.S. Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy DRTS?
Source: Newsfilter
- Milestone Enrollment: Alpha Tau has completed enrollment of 88 patients in the ReSTART trial, marking a significant step towards potential FDA pre-market approval, which is expected to accelerate the commercialization of Alpha DaRT.
- Clinical Trial Context: This trial is the first pivotal clinical study in the U.S. for recurrent cutaneous squamous cell carcinoma, building on clinical data from Israel, Italy, and France, demonstrating the efficacy and safety of Alpha DaRT, addressing urgent patient needs for new therapies.
- Treatment Demand: Recurrent cutaneous squamous cell carcinoma is the second most common form of skin cancer, with rising incidence rates, and existing treatment options failing to meet patient needs; Alpha DaRT aims to provide new treatment options for this underserved population.
- Future Outlook: With enrollment complete, the ReSTART trial will proceed to the follow-up phase, and Alpha Tau will continue to advance its modular PMA application, looking forward to the potential market launch of Alpha DaRT in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRTS
Wall Street analysts forecast DRTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.510
Low
5.00
Averages
7.00
High
9.00
Current: 8.510
Low
5.00
Averages
7.00
High
9.00
About DRTS
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Tau Medical to Discuss Interim Data on Brain Cancer Treatment
- Clinical Trial Progress: Alpha Tau Medical is set to discuss interim data from its U.S. Regain study involving three patients, evaluating Alpha DaRT for recurrent glioblastoma, highlighting the company's potential in brain cancer treatment.
- FDA Certification Acceleration: The company has received Breakthrough Device Designation from the FDA and submitted the first section of its pre-market approval application in January, indicating significant progress in regulatory approval that may expedite market entry.
- Positive Market Reaction: Alpha Tau's shares rose over 1% in Monday's trading, despite ending last week slightly lower at $8.51, reflecting strong investor interest in the company's early clinical results and the innovative nature of its treatment.
- Data Presentation Attracts Investors: The updated pancreatic cancer data presented at Digestive Disease Week showed all 19 evaluable patients achieved local disease control with a 21% partial response rate, further boosting investor confidence in the efficacy of Alpha DaRT treatment.
See More
Alpha Tau Medical Reports Promising Trial Results for Glioblastoma Treatment
- Clinical Trial Results: In the U.S. REGAIN trial, two of the three patients achieved complete responses, with MRI scans confirming the disappearance of all visible tumor lesions, while the third patient showed a 30% reduction in tumor size, indicating Alpha DaRT's potential in treating recurrent glioblastoma.
- Safety Assessment: As of May 3, 2026, Alpha Tau reported no unexpected serious adverse events, although one patient experienced a treatment-related seizure, which was resolved with steroid treatment, supporting the safety profile of the therapy.
- Positive Market Reaction: Shares of Alpha Tau Medical (DRTS) surged over 20% in pre-market trading on Monday, and if this level holds at market open, DRTS stock would reach its highest levels since August 2022, reflecting optimistic market sentiment towards the clinical data.
- Expanded Trial Plans: The FDA recently approved the expansion of Alpha Tau Medical's IMPACT pancreatic cancer trial testing Alpha DaRT in combination with chemotherapy, aimed at evaluating the therapy's safety and tolerability while monitoring tumor response and survival outcomes, showcasing the company's ongoing innovation in cancer treatment.
See More
Alpha Tau Medical Shares Surge 12% on Positive Glioblastoma Trial Results
- Clinical Trial Progress: Alpha Tau Medical's REGAIN trial for recurrent glioblastoma has reported encouraging interim results, with two out of three treated patients achieving complete response, indicating the therapy's efficacy and safety as all enhancing tumor lesions disappeared on multiple post-treatment MRI scans.
- Strong Market Reaction: Following the interim results, Alpha Tau's shares surged over 12% in premarket trading to $9.60, reflecting increased investor confidence in the company's treatment approach, which may drive future capital inflows.
- Survival Rate Challenges: Glioblastoma is the most common and aggressive form of brain cancer, with an average survival rate of only 8 months, while the REGAIN trial aims to treat 10 patients, showcasing the company's potential in addressing this complex disease.
- Optimistic Strategic Outlook: Chief Medical Officer Robert Den expressed gratification at the interim results, especially given the typical survival of under 12 months post-recurrence, providing strong rationale to advance the trial, potentially paving the way for future clinical applications.
See More
Trump Rejects Iran's Revised Proposal Amid Geopolitical Tensions
- Trump's Proposal Rejection: Trump labeled Iran's latest sanctions relief and uranium export proposal as 'totally unacceptable' on social media, potentially escalating tensions in the Middle East and impacting global market sentiment.
- Market Reaction: U.S. stock futures edged lower on Monday morning, with S&P 500 and Dow futures declining by 0.1% while Nasdaq futures remained flat, indicating investor caution ahead of upcoming economic data amid geopolitical developments.
- Chip Sector Momentum: Memory chip stocks like Micron (MU) and Everspin (MRAM) continued to dominate retail chatter, with Everspin's stock surging 35% in early trading, reflecting strong momentum in the AI infrastructure trade.
- Biotech Stocks in Focus: Biotech stocks such as Moderna (MRNA) and Novavax (NVAX) garnered attention, while MoonLake Immunotherapeutics (MLTX) trended high after a positive FDA meeting, showcasing investor confidence in new drug developments.
See More
Alpha Tau Announces Interim Clinical Data for Alpha DaRT
- Clinical Trial Announcement: Alpha Tau Medical has scheduled a conference call on May 11, 2026, to discuss interim clinical data from its Alpha DaRT treatment for recurrent glioblastoma, which is expected to provide critical insights for future treatment protocols.
- Patient Recruitment Strategy: The REGAIN trial aims to enroll up to ten patients with recurrent glioblastoma who are not candidates for surgical resection after prior central nervous system radiation, indicating a significant market need for this treatment.
- Technology Overview: The Alpha DaRT technology utilizes intratumoral delivery of radium-224 sources to achieve highly effective irradiation of tumors while minimizing damage to surrounding healthy tissue, showcasing its substantial therapeutic potential.
- Company Growth Prospects: Founded in 2016, Alpha Tau has focused on oncology therapeutics development, and as clinical trials progress, it is expected to enhance its competitive position in the cancer treatment market.
See More
Alpha Tau Completes Enrollment in Pivotal U.S. Trial
- Milestone Enrollment: Alpha Tau has completed enrollment of 88 patients in the ReSTART trial, marking a significant step towards potential FDA pre-market approval, which is expected to accelerate the commercialization of Alpha DaRT.
- Clinical Trial Context: This trial is the first pivotal clinical study in the U.S. for recurrent cutaneous squamous cell carcinoma, building on clinical data from Israel, Italy, and France, demonstrating the efficacy and safety of Alpha DaRT, addressing urgent patient needs for new therapies.
- Treatment Demand: Recurrent cutaneous squamous cell carcinoma is the second most common form of skin cancer, with rising incidence rates, and existing treatment options failing to meet patient needs; Alpha DaRT aims to provide new treatment options for this underserved population.
- Future Outlook: With enrollment complete, the ReSTART trial will proceed to the follow-up phase, and Alpha Tau will continue to advance its modular PMA application, looking forward to the potential market launch of Alpha DaRT in the future.
See More
Alpha Tau Medical to Discuss Interim Data on Brain Cancer Treatment
- Clinical Trial Progress: Alpha Tau Medical is set to discuss interim data from its U.S. Regain study involving three patients, evaluating Alpha DaRT for recurrent glioblastoma, highlighting the company's potential in brain cancer treatment.
- FDA Certification Acceleration: The company has received Breakthrough Device Designation from the FDA and submitted the first section of its pre-market approval application in January, indicating significant progress in regulatory approval that may expedite market entry.
- Positive Market Reaction: Alpha Tau's shares rose over 1% in Monday's trading, despite ending last week slightly lower at $8.51, reflecting strong investor interest in the company's early clinical results and the innovative nature of its treatment.
- Data Presentation Attracts Investors: The updated pancreatic cancer data presented at Digestive Disease Week showed all 19 evaluable patients achieved local disease control with a 21% partial response rate, further boosting investor confidence in the efficacy of Alpha DaRT treatment.
See More
Alpha Tau Medical Reports Promising Trial Results for Glioblastoma Treatment
- Clinical Trial Results: In the U.S. REGAIN trial, two of the three patients achieved complete responses, with MRI scans confirming the disappearance of all visible tumor lesions, while the third patient showed a 30% reduction in tumor size, indicating Alpha DaRT's potential in treating recurrent glioblastoma.
- Safety Assessment: As of May 3, 2026, Alpha Tau reported no unexpected serious adverse events, although one patient experienced a treatment-related seizure, which was resolved with steroid treatment, supporting the safety profile of the therapy.
- Positive Market Reaction: Shares of Alpha Tau Medical (DRTS) surged over 20% in pre-market trading on Monday, and if this level holds at market open, DRTS stock would reach its highest levels since August 2022, reflecting optimistic market sentiment towards the clinical data.
- Expanded Trial Plans: The FDA recently approved the expansion of Alpha Tau Medical's IMPACT pancreatic cancer trial testing Alpha DaRT in combination with chemotherapy, aimed at evaluating the therapy's safety and tolerability while monitoring tumor response and survival outcomes, showcasing the company's ongoing innovation in cancer treatment.
See More
Alpha Tau Medical Shares Surge 12% on Positive Glioblastoma Trial Results
- Clinical Trial Progress: Alpha Tau Medical's REGAIN trial for recurrent glioblastoma has reported encouraging interim results, with two out of three treated patients achieving complete response, indicating the therapy's efficacy and safety as all enhancing tumor lesions disappeared on multiple post-treatment MRI scans.
- Strong Market Reaction: Following the interim results, Alpha Tau's shares surged over 12% in premarket trading to $9.60, reflecting increased investor confidence in the company's treatment approach, which may drive future capital inflows.
- Survival Rate Challenges: Glioblastoma is the most common and aggressive form of brain cancer, with an average survival rate of only 8 months, while the REGAIN trial aims to treat 10 patients, showcasing the company's potential in addressing this complex disease.
- Optimistic Strategic Outlook: Chief Medical Officer Robert Den expressed gratification at the interim results, especially given the typical survival of under 12 months post-recurrence, providing strong rationale to advance the trial, potentially paving the way for future clinical applications.
See More
Trump Rejects Iran's Revised Proposal Amid Geopolitical Tensions
- Trump's Proposal Rejection: Trump labeled Iran's latest sanctions relief and uranium export proposal as 'totally unacceptable' on social media, potentially escalating tensions in the Middle East and impacting global market sentiment.
- Market Reaction: U.S. stock futures edged lower on Monday morning, with S&P 500 and Dow futures declining by 0.1% while Nasdaq futures remained flat, indicating investor caution ahead of upcoming economic data amid geopolitical developments.
- Chip Sector Momentum: Memory chip stocks like Micron (MU) and Everspin (MRAM) continued to dominate retail chatter, with Everspin's stock surging 35% in early trading, reflecting strong momentum in the AI infrastructure trade.
- Biotech Stocks in Focus: Biotech stocks such as Moderna (MRNA) and Novavax (NVAX) garnered attention, while MoonLake Immunotherapeutics (MLTX) trended high after a positive FDA meeting, showcasing investor confidence in new drug developments.
See More
Alpha Tau Announces Interim Clinical Data for Alpha DaRT
- Clinical Trial Announcement: Alpha Tau Medical has scheduled a conference call on May 11, 2026, to discuss interim clinical data from its Alpha DaRT treatment for recurrent glioblastoma, which is expected to provide critical insights for future treatment protocols.
- Patient Recruitment Strategy: The REGAIN trial aims to enroll up to ten patients with recurrent glioblastoma who are not candidates for surgical resection after prior central nervous system radiation, indicating a significant market need for this treatment.
- Technology Overview: The Alpha DaRT technology utilizes intratumoral delivery of radium-224 sources to achieve highly effective irradiation of tumors while minimizing damage to surrounding healthy tissue, showcasing its substantial therapeutic potential.
- Company Growth Prospects: Founded in 2016, Alpha Tau has focused on oncology therapeutics development, and as clinical trials progress, it is expected to enhance its competitive position in the cancer treatment market.
See More
Alpha Tau Completes Enrollment in Pivotal U.S. Trial
- Milestone Enrollment: Alpha Tau has completed enrollment of 88 patients in the ReSTART trial, marking a significant step towards potential FDA pre-market approval, which is expected to accelerate the commercialization of Alpha DaRT.
- Clinical Trial Context: This trial is the first pivotal clinical study in the U.S. for recurrent cutaneous squamous cell carcinoma, building on clinical data from Israel, Italy, and France, demonstrating the efficacy and safety of Alpha DaRT, addressing urgent patient needs for new therapies.
- Treatment Demand: Recurrent cutaneous squamous cell carcinoma is the second most common form of skin cancer, with rising incidence rates, and existing treatment options failing to meet patient needs; Alpha DaRT aims to provide new treatment options for this underserved population.
- Future Outlook: With enrollment complete, the ReSTART trial will proceed to the follow-up phase, and Alpha Tau will continue to advance its modular PMA application, looking forward to the potential market launch of Alpha DaRT in the future.
See More
